PRC2 as the Convergent Epigenetic Node Driving Multiple Hallmarks of Aging
Hypothesis
PRC2 destabilization is the convergent epigenetic node where diverse stressors trigger heterochromatin collapse, leading simultaneously to mitochondrial dysfunction, stem cell exhaustion, and SASP.
Mechanistic Rationale
Loss of EZH2 catalytic activity reduces H3K27me3 at pericentromeric repeats, permitting transcription of satellite RNAs and endogenous retrotransposons. These nucleic acids activate the cGAS‑STING pathway, consuming NAD+ and impairing mitochondrial respiration while driving IFN‑stimulated SASP genes {1}. Parallelly, H3K27me3 loss at Polycomb target loci de‑represses differentiation inhibitors, biasing stem cells toward senescence and depleting the regenerative pool {2}. Direct causal evidence linking H3K27me3 loss to downstream hallmarks remains sparse {3}. Thus, PRC2 dysfunction explains why disparate insults (replicative stress, oncogene activation, metabolic overload) converge on the same downstream hallmarks.
Testable Predictions
- Pharmacological stabilization of PRC2 (e.g., EZH2 activator or SAM supplementation) will reduce cytosolic dsDNA, lower cGAS‑STING signaling, and rescue mitochondrial membrane potential across RS, OIS, and stress‑induced senescence.
- EZH2 overexpression in aged murine stem cells will retain H3K27me3 at retrotransposon loci, diminish SASP secretion, and improve functional repopulation in transplantation assays.
- Conversely, acute EZH2 inhibition will phenocopy multi‑hallmark decline even in the absence of external stressors, confirming sufficiency.
Experimental Design
- In vitro: Human fibroblasts subjected to RS (passaging), OIS (RAS^V12), or metabolic stress (high glucose/palmitate). Treat groups with EZH2 activator (e.g., EZH2‑A) or vehicle. Measure H3K27me3 (Western blot), cytoplasmic dsDNA (IF for dsDNA), p‑STING, MitoSOX ROS, OCR/ECAR (Seahorse), SASP cytokines (ELISA), and SA‑β‑gal.
- In vivo: Aged EZH2‑transgenic mice vs littermates. Assess stem cell compartments (HSC, MSC) by flow cytometry, tissue histology, serum IL‑6, and frailty index. Include a group treated with EZH2 inhibitor (GSK126) to test sufficiency.
- Controls: Use catalytically dead EZH2 mutant to distinguish enzymatic vs scaffolding effects.
Potential Pitfalls
Compensatory changes in other histone methyltransferases could mask EZH2 effects; therefore, include EZH1 knockdown controls. Off‑target metabolic effects of SAM supplementation should be monitored via metabolomics. Mouse model may not fully recapitulate human senescence heterogeneity; validate with human organoid cultures.
References
[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC11748698/ [2] https://doi.org/10.1101/gad.223834.113 [3] https://academic.oup.com/nar/article/50/19/10947/6761724